DISP-35. Origin-Based Differences in Outcomes Among Hispanic Patients with Glioblastoma

Abstract BACKGROUND Hispanic individuals in the United States harbor distinct cultural, socioeconomic, and health profiles that may influence cancer outcomes. While disparities have been observed in other malignancies, the role of specific Hispanic origin in glioblastoma (GBM) outcomes remains underexplored. We conducted a population-based retrospective study to investigate whether country of origin is associated with differences in treatment and survival among Hispanic patients with GBM. METHODS Using the National Cancer Database (2004-2022), we observed 10,321 self-identified Hispanic patients diagnosed with GBM. Origins were classified as Mexican, Puerto Rican, Cuban, South or Central American (excluding Brazil), Dominican Republic, or other. Multivariable logistic regressions assessed associations between origin and systemic therapy use, adjusting for age, insurance type, comorbidities, facility type, and radiation therapy. Cox proportional hazards models were used to evaluate overall survival (OS), and Kaplan-Meier analysis with log-rank testing compared survival curves across origin groups. RESULTS Regression analysis revealed that Hispanic origin was independently associated with variation in systemic therapy use and survival outcomes, with some origin groups experiencing significantly improved OS compared to others. After adjusting of demographics and treatment-related factors, patients from South or Central America (HR: 0.76; 95% CI: 0.68-0.85; P <0.001), the Dominican Republic (HR 0.66; 95% CI, 0.55–0.79; P <0.001), and Other Hispanic groups (HR: 0.78; 95% CI: 0.67-0.92; P=0.002) had significantly improved survival compared to Mexican patients. Median OS ranged from 10.87 months (Cuban origin) to 15.18 months (South/Central American origin). A log-rank test confirmed significant survival differences by origin (P<0.001). CONCLUSIONS This retrospective population-based study reveals that among Hispanic patients with GBM, country of origin is significantly associated with survival and treatment utilization. These findings underscore the critical need to disaggregate Hispanic populations in neuro-oncology research and to develop targeted strategies that address origin-specific disparities in access to care and prognosis.